Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients

International Journal of Laboratory Hematology

Volumn 32, Issue 2, 2010, Pages 142-149

  Ozalp Yuregir, O ^a   Yurtcu, E ^a   Kizilkilic, E ^a   Kocer, N E ^a   Ozdogu, H ^a   Sahin, F I ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Bisulfite modification; Epigenetics; Methylation specific polymerase chain reaction; Multiple myeloma; Promoter hypermethylation

Indexed keywords

6 O METHYLGUANINE; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; UVOMORULIN;

ADULT; AGED; ARTICLE; BONE LESION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DAPK GENE; DISEASE COURSE; DNA METHYLATION; E CADHERIN GENE; EPIGENETICS; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; GENE; GENE SILENCING; HUMAN; MALE; MGMT GENE; MULTIPLE MYELOMA; P16 GENE; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CADHERINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77953585334     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2009.01146.x     Document Type: Article

References (22)

1. Batalie R., Boccadoro M., Klein B., Durie B. & Pileri A. (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80, 733-737.
2. Brena R. M. & Costello J. F. (2007) Genome-epigenome interactions in cancer. Human Molecular Genetics 16 (Spec No 1): R96-R105.
3. Chim C. S., Kwong Y. L., Fung T. K. & Liang R. (2004) Methylation profiling in multiple myeloma. Leukemia Research 28, 379-385.
4. Chim C. S., Liang R., Fung T. K., Choi C. L. & Kwong Y. L. (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/ Apaf-1 apoptosis pathway in multiple myeloma. Journal of Clinical Pathology 60, 664-669.
5. Esteller M. (2008) Epigenetics in cancer. New England Journal of Medicine 358, 1148-1159.
6. Esteller M., Garcia-Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B. & Herman J. G. (2000) Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine 343, 1350-1354.
7. Esteller M., Risques R. A., Toyota M., Capella G., Moreno V., Peinado M. A., Baylin S. B. & Herman J. G. (2001) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Research 61, 4689-4692.
8. Galm O. & Herman G. (2005) Methylation specific polymerase chain reaction. In: Multiple Myeloma Methods and Protocols (eds R. D. Brown & P. J. Ho),pp. 279-291. Humana Pres, NJ.
9. Galm O., Wilop S., Reichelt J., Jost E., Gehbauer G., Herman J. G. & Osieka R. (2004) DNA methylation changes in multiple myeloma. Leukemia 18, 1687-1692.
10. Gonzalez-Paz N., Chng W. J., McClure R. F., Blood E., Oken M. M., Van Ness B., James C. D., Kurtin P. J., Henderson K., Ahmann G. J., Gertz M., Lacy M., Dispenzieri A., Greipp P. R. & Fonseca R. (2007) Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109, 1228-1232.
11. Guillerm G., Gyan E., Wolowiec D., Facon T., Avet-Loiseau H., Kuliczkowski K., Bauters F., Fenaux P. & Quesnel B. (2001) p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 98, 244-246.
12. Jacobson J. L., Hussein M. A., Barlogie B., Durie B. G. & Crowley J. J. (2003) A new staging system for multiple myeloma patients based on the South West Oncology Group (SWOG) experience. British Journal Haematology 122, 441-450.
13. Martin P., Santón A., García-Cosio M. & Bellas C. (2006) hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Modern Pathology 19, 914-921.
14. Ng M. H., Chung Y. F., Lo K. W., Wickham N. W., Lee J. C. & Huang D. P. (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89, 2500-2506.
15. Ng M. H., To K. W., Lo K. W., Chan S., Tsang K. S., Cheng S. H. & Ng H. K. (2001) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clinical Cancer Research 7, 1724-1729.
16. Qi J., Zhu Y. Q., Huang M. F. & Yang D. (2005) Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World Journal of Gastroenterology 11, 2022-2025.
17. Raveh T. & Kimchi A. (2001) DAP kinasea proapoptotic gene that functions as a tumor suppressor. Experimental Cell Research 264, 185-192.
18. Rossi D., Capello D., Gloghini A., Franceschetti S., Paulli M., Bhatia K., Saglio G., Vitolo U., Pileri S. A., Esteller M., Carbone A. & Gaidano G. (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89, 154-164.
19. Seidl S., Kaufmann H. & Drach J. (2003) New insights into the pathophysiology of multiple myeloma. Lancet Oncol 4, 557-564.
20. Seidl S., Ackermann J., Kaufmann H., Keck A., Nösslinger T., Zielinski C. C., Drach J. & Zöchbauer-Müller S. (2004) DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 100, 2598-2606.
21. Smadja N. V., Bastard C., Brigaudeau C., Leroux D., Fruchart C. & Groupe Français de Cytogénétique Hématologique. (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98, 2229-2238.
22. Smith A., Wisloff F., Samson D. & UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. (2006) Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal Haematology 132, 410-451.